• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
STRO

STRO

Sutro Biopharma, Inc.

NASDAQHealthcareBiotechnologyUS

USD27.18

+2.75 (+11.26%)

Rating:C

Company Profile

CEO

Jane Chung

IPO Date

2018-09-27

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$24.52

Prev. Close

$24.43

Day Low

$23.63

Day High

$27.20

52W Low

$6.70

52W High

$43.85

Market Cap

$0.26B

Volume

0.44M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

35.1%

Avg Negative

1.7%

Avg Neutral

63.2%

News Feed

Sutro Biopharma to Participate in the 12th Annual Wedbush PacGrow Healthcare Virtual Conference

PRNewsWire·7/29/2021·↑ positive

Sutro Biopharma, Inc. (STRO) Surges 6.4%: Is This an Indication of Further Gains?

Zacks Investment Research·6/21/2021·↑ positive

Sutro Biopharma to Participate in Two Virtual Investor Conferences in June

PRNewsWire·6/15/2021·↑ positive

Sutro Biopharma Earns Milestone Payment from Bispecific Antibody-Drug Conjugate Collaboration with Merck KGaA, Darmstadt, Germany

PRNewsWire·6/1/2021·↑ positive

Sutro Biopharma Announces Additional Data for Dose-Escalation Phase 1 Study of STRO-002 to be Presented at ASCO 2021

PRNewsWire·5/19/2021·↑ positive

Sutro Biopharma to Participate in Upcoming Virtual Investor Conferences

PRNewsWire·5/14/2021·↑ positive

Sutro Biopharma Reports First Quarter 2021 Financial Results, Business Highlights and 2021 Anticipated Milestones

PRNewsWire·5/7/2021·↑ positive

Sutro Biopharma Earns Milestone Payment from Cytokine Derivatives Collaboration with Merck

PRNewsWire·4/15/2021·↑ positive

Sutro Biopharma to Present at Two Upcoming Investor Conferences

PRNewsWire·4/8/2021·↑ positive

Sutro Biopharma Strengthens Leadership Through Management Promotions and Expansion of Clinical Advisory Board

PRNewsWire·3/22/2021·↑ positive